Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens

Statistics in Medicine

Volumn 17, Issue 3, 1998, Pages 251-267

  Urquhart, John ^a,c   De Klerk, Erik ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG DOSE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; SIDE EFFECT; TREATMENT OUTCOME;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG MONITORING; DRUG THERAPY; HUMANS; PATIENT COMPLIANCE;

EID: 0032520248     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19980215)17:3<251::AID-SIM762>3.0.CO;2-A     Document Type: Conference Paper

References (64)

1. Rangno, R. E. and Langlois, S. 'Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol', American Heart Journal, 104, 473-478 (1982).
2. Psaty, B. M., Koepsell, T. D., Wagner, E. H., LoGerfo, J. P. and Inui, T. S. 'The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers', Journal of the American Medical Association, 263, 1653-1657 (1990).
3. Anon. 'Long-term use of beta blockers: the need for sustained compliance', World Health Organization Drug Information, 4, (2), 52-53 (1990).
4. Urquhart, J. 'Role of patient compliance in clinical pharmacokinetics: review of recent research', Clinical Pharmacokinetics, 27, 202-215 (1994).
5. Lasagna, L. 'Noncompliance data and clinical outcomes: impact on health care', Primary Cardiology, 18, (Supplement 1), 36-39 (1992).
6. Feinstein, A. R. 'On white-coat effects and the electronic monitoring of compliance', Archives of Internal Medicine, 150, 1377-1378 (1990).
7. Pullar, T. and Feely, M. 'Problems of compliance with drug treatment: new solutions?', Pharmaceutical Journal, 245, 213-215 (1990).
8. Bond, W. S. and Hussar, D. A. 'Detection methods and strategies for improving medication compliance', American Journal of Hospital Pharmacy, 48, 1978-1988 (1991).
9. Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991.
10. Vander Stichele, R. 'Measurement of patient compliance and the interpretation of randomized clinical trials', European Journal of Clinical Pharmacology, 41, 27-35 (1991).
11. Kruse, W. 'Patient compliance with drug treatment - new perspectives on an old problem', Clinical Investigation, 70, 163-166 (1992).
12. Rudd, P. 'Compliance with antihypertensive therapy: a shifting paradigm', Cardiology in Review, 2, 230-240 (1994).
13. Cramer, J. A. 'Compliance with contraceptives and other treatments', Obstetrics and Gynecology, 88(3), Suppl., 45-125 (1996).
14. Glover, F. United States Patent 4,034,757, 1976.
15. Kass, M. A., Meltzer, D. and Gordon, M. 'A miniature compliance monitor for opthalmology', Archives of Opthalmology, 102, 1550 (1984).
16. Vander Stichele, R. H., Thomson, M., Verkoelen, K. and Droussin, A. M. 'Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in essential hypertension', Post-marketing Surveillance, 6, 77-90 (1992).
17. Kass, M. A., Zimmerman, T., Yablonski, M. and Becker, B. 'Compliance to pilocarpine therapy', Investigative Opthalmology (Association for Research in Vision and Opthalmology Abstracts Supplement), 108, abstract 2 (1977).
18. Kass, M. A., Meltzer, D., Gordon, M., Cooper, D. and Goldberg, J. 'Compliance with topical pilocarpine treatment', American Journal of Opthalmology, 101, 515-523 (1986).
19. Kass, M. A., Gordon, M. and Meltzer, D. W. 'Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy?', American Journal of Opthalmology, 101, 524-530 (1986).
20. Kass, M. A., Gordon, M., Morley, R. E., Meltzer, D. W. and Goldberg, J. J. 'Compliance with topical timolol treatment', American Journal of Opthalmology, 103, 188-193 (1987).
21. Cramer, J. A., Mattson, R. H., Prevey, M. L., Scheyer, R. D. and Ouellette, V. L. 'How often is medication taken as prescribed? A novel assessment technique', Journal of the American Medical Association, 261, 3273-3277 (1989).
22. Kruse, W. and Weber, E. 'Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring', European Journal of Clinical Pharmacology, 38, 561-565 (1990).
23. Averbuch, M., Weintraub, M. and Pollack, D. J. 'Compliance assessment in clinical trials: the MEMS device', Journal of Clinical Research and Pharmacoepidemiology, 4, 199-204 (1990).
24. Eisen, S. A., Woodward, R. S., Miller, D., Spitznagel, E. and Windham, C. A. 'The effect of medication compliance on the control of hypertension', Journal of General Internal Medicine, 2, 298-305 (1987).
25. Cheung, R., Dickins, J., Nicholson, P. W., Thomas, A. S. C., Smith, H. H., Larson, H. E., Deshmukh, A. A., Dobbs, R. J. and Dobbs, S. M. 'Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed recording device', European Journal of Clinical Pharmacology, 35, 401-407 (1988).
26. Tashkin, D. P., Rand, C., Nides, M., Simmons, M., Wise, R., Coulson, A. H., Li, V. and Gong, H., Jr. 'A nebulizer chronolog to monitor compliance with inhaler use', Amercian Journal of Medicine, 91, (suppl 4A), 33S-36S (1991).
27. Cramer, J. A., Ouelette, V. L. and Mattson, R. H. 'The effect of microelectronic observation on compliance', Epilepsia, 31, 617-618 (1990).
28. Compliance, Infratest AG, Munich, Germany, 1990.
29. 'Phenobarbital pharmacokinetic data, Table A-II-1' in Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, McGraw-Hill, New York, 1996, p. 1770.
30. Cramer, J. A., Scheyer, R. D. and Mattson, R. H. 'Compliance declines between clinic visits', Archives of Internal Medicine, 150, 1509-1510 (1990).
31. Feely, M., Cooke, J., Price, D., Singleton, S., Mehta, A., Bradford, L. and Calvert, R. 'Low-dose phenobarbitone as an indicator of compliance with drug therapy', British Journal of Clinical Pharmacology, 24, 77-83 (1987).
32. Benet, L. Z., Kroetz, D. L. and Sheiner, L. B. 'Clearance', in Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, McGraw-Hill, New York, 1996, pp. 18-20.
33. Waterhouse, D. M., Calzone, K. A., Mele, C. and Brenner, D. E. 'Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring', Journal of Clinical Oncology, 11, 1189-1197 (1993).
34. Guerrero, D., Rudd, P., Bryant-Kosling, C. and Middleton, B. F. 'Antihypertensive medication-taking. Investigation of a simple regimen', American Journal of Hypertension, 6, 586-592 (1993).
35. Kruse, W., Nikolaus, T., Rampmaier, J., Weber, E. and Schlierf, G. 'Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring', European Journal of Clinical Pharmacology, 44, 211-215 (1993).
36. Pullar, T., Kumar, S., Tindall, H. and Feely, M. 'Time to stop counting the tablets?', Clinical Pharmacology and Therapeutics, 46, 163-168 (1989).
37. Urquhart, J. 'Partial compliance in cardiovascular disease: risk implications', British Journal of Clinical Practice, Suppl 73, 2-12 (1994).
38. de Klerk, E. and van der Linden, Sj, 'Compliance monitoring of NSAID drug-therapy in ankylosing spondylitis, experiences with an electronic monitoring device', British Journal of Rheumatology, 35 60-65 (1996).
39. Cramer, J. A. and Mattson, R. H. 'Monitoring compliance with antiepileptic drug therapy', in Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991, pp. 123-137.
40. Urquhart, J. 'Correlates of variable patient compliance in drug trials: relevance in the new health care environment', in Testa, B. and Meyer, U. A. (eds), Advances in Drug Research, Academic Press, London 1995, pp. 238-257.
41. Urquhart, J. 'Time to take our medicines, seriously', Pharmaceutisch Weekblad, 127, 769-776 (1992).
42. Kleinbloesem, C. H., van Brummelen, P., Danhof, M., Faber, H., Urquhart, J. and Breimer, D. D. 'Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans', Clinical Pharmacology and Therapeutics, 41, 26-30 (1987).
43. Breimer, D. D. and Urquhart, J. 'Nifedipine GITS', Lancet, 341, 306 (1993).
44. Potter, L. S. 'Oral contraceptive compliance and its role in the effectiveness of the method', in Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York 1991, pp. 195-207.
45. Guillebaud, J. 'Any questions?', British Medical Journal, 307, 617 (1993).
46. Johnson, B. F. and Whelton, A. 'A study design for comparing the effects of missing daily doses of antihypertensive drugs', American Journal of Therapeutics, 1, 260-267 (1994).
47. Urquhart, J. 'Patient compliance as an explanatory variable in four selected cardiovascular studies', in Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991, pp. 301-322.
48. Meier, P. 'Discussion', Journal of the American Statistical Association, 86, (413), 19-22 (1991).
49. Kruse, W., Rampmaier, J., Ullrich, G. and Weber, E. 'Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care', International Journal of Clinical Pharmacology and Therapeutics, 32, 453-457 (1994).
50. Levy, G. 'A pharmacokinetic perspective on medicament noncompliance', Clinical Pharmacology and Therapeutics, 54, 242-244 (1993).
51. Efron, B. and Feldman, D. 'Compliance as an explanatory variable in clinical trials', Journal of the American Statistical Association, 86, 7-17 (1991).
52. Zeger, S. L. and Liang, K.-Y. 'Comment: dose-response estimands', Journal of the American Statistical Association, 86, 18-19 (1991).
53. Rubin, D. 'Comment: dose-response estimands', Journal of the American Statistical Association, 86, 22-24 (1991).
54. Hasford, J. 'Biometric issues in measuring and analyzing partial compliance in clinical trials', in Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991, pp. 265-281.
55. Hasford, J. 'Compliance bei Klinischen Prüfungen', in Hasford, J. and Staib, A. H. (eds), Arzneimittelprüfungen und Good Clinical Practice, MMV Medizin Verlag, Munich, 1994, pp. 166-178.
56. Sheiner, L. B. 'The intellectual health of clinical drug evaluation', Clinical Pharmacology and Therapeutics, 50, 4-9 (1991).
57. Sheiner, L. B. and Rubin, D. B. 'Intention to treat analysis and the goals of clinical trials', Clinical Pharmacology and Therapeutics, 57, 6-15 (1995).
58. Goetghebeur, E. J .T. and Pocock, S. J. 'Statistical issues in allowing for noncompliance and withdrawal', Drug Information Journal, 27, 837-845 (1993).
59. Petri, H. and Urquhart, J. 'Patient compliance with beta-blocker medication in general practice', Pharmacoepidemiology and Drug Safety, 3, 251-256 (1994).
60. Lasagna, L. and Hutt, P. B. 'Health care, research, and regulatory impact of noncompliance', in Cramer, J. A. and Spilker, B. (eds), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991, pp. 393-403.
61. 'QUESTRAN (cholestyramine)', in Physician's Desk Reference, Medical Economics Co., Montvale, NJ, 1996, pp. 770-771.
62. Anon. 'The lipid Research Clinics Coronary Primary Prevention Trial results: (I) Reduction in incidence of coronary heart disease; (II) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering', Journal of the American Medical Association, 251, 351-374 (1984).
63. Peck, C. C., Barr, W. H., Benet, L. Z., Collins, K., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T., Rodman, J. H., Sanathanan, L., Schentag, J. J., Shah, V. P., Sheiner, L. B., Skelly, J. P., Stanski, D. R., Temple, R. J., Viswanathan, C. T., Weissinger, J. and Yacobi, A. 'Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development', Clinical Pharmacology and Therapeutics, 51, 465-473 (1992).
64. Leape, L. L., Bates, D. W., Cullen, D. J., Cooper, J., Demonaco, G., Nemeskal, R., Petersen, L. A., Porter, K., Servi, D., Shea, B. F., Small, S. D., Sweitzer, B. J., Thompson, B. T. and Vander Vliet, M. 'Systems analysis of adverse drug effects', Journal of the American Medical Association, 274, 35-43 (1995).